Price Chart

Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
URL https://www.gilead.com
Investor Relations URL https://investors.gilead.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Large Cap/Value
Next Earnings Release Feb. 06, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date Dec. 13, 2024
Last Ex-Dividend Date Sep. 13, 2024

Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
URL https://www.gilead.com
Investor Relations URL https://investors.gilead.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Large Cap/Value
Next Earnings Release Feb. 06, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date Dec. 13, 2024
Last Ex-Dividend Date Sep. 13, 2024